Nordic Nanovector AS: Final result of the subsequent offering
Reference is made to the announcement by Nordic Nanovector (the “Company) on 15 September 2014. The subsequent repair offering (the “Offering”) of up to 2,000,000 new shares at a subscription price of NOK 25 per share was oversubscribed by approximately 35%.
The final allocation of the new shares offered in the Offering has taken place today in accordance with the allocation criteria set out in the resolutions made by the general meeting of the Company held on 27 June 2014 (see the prospectus dated 28 August 2014). A total of 2,000,000 new shares have been allocated. Gross proceeds from the Offering will be NOK 50 million (USD 7,8 million).
The new shares have only been allocated to Eligible Shareholders (as defined in the prospectus dated 28 August 2014). Notifications of allocated new shares and the corresponding subscription amount to be paid by each Eligible Shareholder are expected to be distributed today. Payment for the allocated new shares falls due on 18 September 2014.
The new shares may not be transferred or traded before they are fully paid and the share capital increase pertaining to the Offering has been registered with the Norwegian Register of Business Enterprises, expected to take place on or about 22 September 2014.
ABG Sundal Collier and DNB Markets acted as managers for the Offering.
Tone Kvåle, CFO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 91 51 95 76
Fax: ( 47) 22 58 00 07
E-mail: tkv@nordicnanovector.no
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
Tags:
